Key Highlights
- Revenue was USD 12.87 million against an estimate of USD 14.62 million.
- Loss per share was USD 0.81 against an estimate of a USD 0.72 loss.
- Net loss was USD 23.72 million, compared with USD 18.70 million.
- Cash and marketable securities were USD 194.5 million at September 30, 2026.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported total Revenue of USD 12.9 million for the fiscal fourth quarter ended September 30, 2026, compared with USD 15.1 million in the prior-year quarter, against an estimate of USD 14.62 million. Basic and diluted net loss per share was USD 0.81, compared with USD 0.87, against an estimate of a USD 0.72 loss.
Net loss was USD 23.72 million, compared with USD 18.70 million. The company described itself as a clinical-stage biotechnology company creating small molecule drugs for viral infections and immunological diseases.
Fiscal Fourth Quarter Results
Revenue consisted of Royalty revenue derived from worldwide net sales of AbbVie's hepatitis C virus regimen MAVYRET/MAVIRET. The company stated that the decrease in quarterly and annual revenue was due to a decline in those sales. A portion of 54.5% of ongoing royalty revenue is paid to OMERS under a royalty sale transaction, which is treated as Debt for financial reporting purposes.
Research and development expenses were USD 26.1 million, compared with USD 23.8 million, which the company attributed to higher clinical trial expenses for its RSV programs, including the RESOLVE and LOTUS studies. General and administrative expenses were USD 8.8 million, compared with USD 9.7 million, reflecting lower stock-based compensation and lower legal expenses related to its Patent infringement lawsuit against Pfizer. Interest expense was USD 3.5 million, compared with USD 2.4 million, and interest and Investment income, net, was USD 1.8 million, compared with USD 2.1 million. The loss from operations was USD 22.04 million, compared with USD 18.39 million.
Fiscal Year 2026 Results
For the twelve months ended September 30, 2026, total revenue was USD 63.0 million, compared with USD 65.3 million. Research and Development expenses were USD 88.5 million, compared with USD 106.7 million, which the company attributed to the timing of clinical trial expenses for its RSV programs, partly offset by higher costs for immunology programs. General and administrative expenses were USD 36.8 million, compared with USD 43.9 million.
The loss from operations for the year was USD 62.38 million, compared with USD 85.35 million, and the net loss was USD 68.25 million, compared with USD 81.89 million. Basic and diluted net loss per share for the year was USD 2.35, compared with USD 3.84.
Pipeline Updates and Balance Sheet
The company completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients with RSV, with topline data anticipated in the first quarter of 2027. It also initiated dosing in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe RSV outcomes, with topline Phase 2b data anticipated in 2027. Topline Phase 1 data for EDP-978, an oral KIT inhibitor, is anticipated in the first quarter of 2027, and an IND filing for EDP-903, an oral STAT6 inhibitor, is anticipated in the second quarter of 2027. The company selected EPS-5336 as an MRGPRX2 development candidate, with an IND filing targeted for the fourth quarter of 2027.
The company announced the planned retirement of its President and CEO by February 2027 and the promotion of Tara L. Kieffer, Ph.D. to Chief Operating Officer. Cash and marketable securities totaled USD 194.5 million at September 30, 2026, and the company anticipates that its cash runway funds operations into fiscal 2029. Cash and cash equivalents were USD 20.27 million, short-term marketable securities were USD 174.24 million, and total Assets were USD 275.58 million. Total liabilities were USD 195.38 million and total stockholders' Equity was USD 80.20 million.
Enanta Pharmaceuticals Fiscal Q4 2026 Earnings: Key Takeaways
Enanta Pharmaceuticals reported fiscal fourth quarter 2026 revenue of USD 12.9 million and a net loss of USD 23.72 million. Cash and marketable securities totaled USD 194.5 million at September 30, 2026.






Please wait processing your request...